Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2018; 39(02): 125-126
DOI: 10.4103/ijmpo.ijmpo_92_17
Editorial Commentary

Adding Olanzapine to Three Drugs Anti Emetic Regimen: Is it Time to Jump the Gun?

Aditi Aggarwal
Department of Radiotherapy and Oncology, Maulana Azad Medical College, New Delhi, India
,
Vinod Sharma
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Sameer Rastogi
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Background

Field of cancer supportive care is rapidly evolving and number of anti-emetic agents has been approved and added to treatment arsenal in the past two decades. Not unexpectedly, in a worldwide online survey (ASCO 2014), antiemetics were voted among the “Top 5 advances in 50 years of modern oncology.”[1] Combination regimen are current standard of care, targeting the polypharmacology of chemotherapy-induced nasua and vomiting (CINV), especially in highly emetogenic chemotherapy regimen (HEC). However, polypharmacy has potential for additive side effects and may not be cost effective. Indeed, one has to focus on strategies, so to achieve the best with the least.



Publication History

Article published online:
23 June 2021

© 2018. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 American Society of Clinical Oncology. ASCO 50th Anniversary Poll Names the Top 5 Advances from the Past 50 Years. Availablefrom: http://www.asco.org/press-center/asco-50th-anniversarypoll-names-top-5-advances-past-50-years. [Last accessed on 2014 Sep 17].
  • 2 Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M. et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016; 375: 134-42
    CrossrefPubMedGoogle Scholar
  • 3 Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A randomized phase III trial. J Support Oncol 2011; 9: 188-95
    CrossrefPubMedGoogle Scholar
  • 4 Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: A dose-ranging clinical study. Ann Oncol 2004; 15: 330-7
    CrossrefPubMedGoogle Scholar
  • 5 Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit RD. et al The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 2005; 41: 1278-85
    CrossrefPubMedGoogle Scholar
  • 6 McDonagh M, Peterson K, Thakurta S. Consideration of Evidence on Antiemetic Drugs for Nausea and Vomiting Associated with Chemotherapy or Radiation Therapy in Adults.(AHRQ Technology Assessments) Rockville (MD): Agency for Healthcare Research and Quality (US); 2010.Available from: http://www.ncbi.nlm.nih.gov/books/NBK254005/. [Last accessed on 2017 May 14]